REG - GSK PLC - Director/PDMR Shareholding

GSKAnnouncement

22/09/2025 15:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250922:nRSV2995Aa&default-theme=true

RNS Number : 2995A  GSK PLC  22 September 2025

GSK plc (the 'Company')

Transaction notification

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Wendy Becker
 b)  Position/status                          Independent Non-Executive Director
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

                                              ISIN: GB00BN7SWP63
 b)  Nature of the transaction                Purchase of 526 Ordinary Shares
 c)  Price(s) and volume(s)                                    Price(s)         Volume(s)
                                                               £15.0300         526

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2025-09-19
 f)  Place of the transaction                 London Stock Exchange (XLON)

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Elizabeth (Liz) McKee Anderson
 b)  Position/status                          Independent Non-Executive Director
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  American Depositary Shares ('ADSs')

                                              ISIN: US37733W2044
 b)  Nature of the transaction                Purchase of 240 ADSs
 c)  Price(s) and volume(s)                                    Price(s)         Volume(s)
                                                               $40.7387         240

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2025-09-19
 f)  Place of the transaction                 New York Stock Exchange (XNYS)

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Charles Bancroft
 b)  Position/status                          Senior Independent Non-Executive Director
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  American Depositary Shares ('ADSs')

                                              ISIN: US37733W2044
 b)  Nature of the transaction                Purchase of 1,880 ADSs
 c)  Price(s) and volume(s)                                    Price(s)         Volume(s)
                                                               $40.7387         1,880

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2025-09-19
 f)  Place of the transaction                 New York Stock Exchange (XNYS)

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Dr Hal Barron
 b)  Position/status                          Non-Executive Director
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  American Depositary Shares ('ADSs')

                                              ISIN: US37733W2044
 b)  Nature of the transaction                Purchase of 240 ADSs
 c)  Price(s) and volume(s)                                    Price(s)         Volume(s)
                                                               $40.7387         240

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2025-09-19
 f)  Place of the transaction                 New York Stock Exchange (XNYS)

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Dr Anne Beal
 b)  Position/status                          Independent Non-Executive Director
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  American Depositary Shares ('ADSs')

                                              ISIN: US37733W2044
 b)  Nature of the transaction                Purchase of 240 ADSs
 c)  Price(s) and volume(s)                                    Price(s)         Volume(s)
                                                               $40.7387         240

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2025-09-19
 f)  Place of the transaction                 New York Stock Exchange (XNYS)

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Dr Hal Dietz
 b)  Position/status                          Independent Non-Executive Director
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  American Depositary Shares ('ADSs')

                                              ISIN: US37733W2044
 b)  Nature of the transaction                Purchase of 240 ADSs
 c)  Price(s) and volume(s)                                    Price(s)         Volume(s)
                                                               $40.7387         240

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2025-09-19
 f)  Place of the transaction                 New York Stock Exchange (XNYS)

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Dr Jeannie Lee
 b)  Position/status                          Independent Non-Executive Director
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  American Depositary Shares ('ADSs')

                                              ISIN: US37733W2044
 b)  Nature of the transaction                Purchase of 239 ADSs
 c)  Price(s) and volume(s)                                    Price(s)         Volume(s)
                                                               $40.7387         239

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2025-09-19
 f)  Place of the transaction                 New York Stock Exchange (XNYS)

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Dr Vishal Sikka
 b)  Position/status                          Independent Non-Executive Director
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  American Depositary Shares ('ADSs')

                                              ISIN: US37733W2044
 b)  Nature of the transaction                Purchase of 827 ADSs
 c)  Price(s) and volume(s)                                    Price(s)         Volume(s)
                                                               $40.7387         827

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2025-09-19
 f)  Place of the transaction                 New York Stock Exchange (XNYS)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHSEUFLEEISESU



            Copyright 2019 Regulatory News Service, all rights reserved